Aspen to Buy Glaxo Drugs for $372 Million as Deal Spree Goes OnBy
South African company signs second deal to add anesthetics
Aspen, Glaxo also agree to end sub-Saharan Africa partnership
Aspen Pharmacare Holdings Ltd. agreed to buy a portfolio of anesthetic medicines from GlaxoSmithKline Plc for as much as 280 million pounds ($372 million) as Africa’s biggest maker of generic drugs continues a spending spree.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.